Log in

NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Forecast & News

$60.13
+0.07 (+0.12 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$59.42
Now: $60.13
$60.33
50-Day Range
$58.32
MA: $60.51
$63.40
52-Week Range
$53.34
Now: $60.13
$86.58
Volume350,469 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio20.04
Dividend YieldN/A
BetaN/A
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:IONS
CUSIP46433010
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees737
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.


Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its quarterly earnings data on Wednesday, November, 6th. The company reported $0.18 earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.49. The firm earned $168 million during the quarter, compared to analysts' expectations of $152.47 million. The company's revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.03) EPS. View Ionis Pharmaceuticals' Earnings History.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Ionis Pharmaceuticals.

What price target have analysts set for IONS?

12 equities research analysts have issued twelve-month target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $48.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $75.82 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

What is the consensus analysts' recommendation for Ionis Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ionis Pharmaceuticals.

Has Ionis Pharmaceuticals been receiving favorable news coverage?

Headlines about IONS stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ionis Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Ionis Pharmaceuticals.

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 8,480,000 shares, an increase of 10.1% from the December 31st total of 7,700,000 shares. Based on an average trading volume of 983,700 shares, the days-to-cover ratio is presently 8.6 days. Currently, 6.6% of the company's shares are sold short. View Ionis Pharmaceuticals' Current Options Chain.

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), BlackRock (BLK), Biogen (BIIB), Gilead Sciences (GILD), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Allergan (AGN).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:
  • Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
  • Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
  • Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
  • Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.90%), Baillie Gifford & Co. (6.25%), BVF Inc. IL (1.55%), Renaissance Technologies LLC (1.45%), First Trust Advisors LP (0.71%) and Sumitomo Mitsui Trust Holdings Inc. (0.69%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Pictet Asset Management Ltd., UBS Group AG, Jacobs Levy Equity Management Inc., Pinnacle Associates Ltd., Bank of America Corp DE, Rafferty Asset Management LLC and Goldman Sachs Group Inc.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Rockefeller Capital Management L.P., Baillie Gifford & Co., Scout Investments Inc., Renaissance Technologies LLC, Rothschild & Co. Asset Management US Inc., Sumitomo Mitsui Trust Holdings Inc. and Amia Capital LLP. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $60.13.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  601 (Vote Outperform)
Underperform Votes:  698 (Vote Underperform)
Total Votes:  1,299
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel